0 XP   0   0   0

Argenica Therapeutics Ltd
Buy, Hold or Sell?

Let's analyse Argenica together

PenkeI guess you are interested in Argenica Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Argenica Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Argenica Therapeutics Ltd

I send you an email if I find something interesting about Argenica Therapeutics Ltd.

Quick analysis of Argenica (30 sec.)










1. Valuation of Argenica (5 min.)




Live pricePrice per share (EOD)

A$0.39

2. Growth of Argenica (5 min.)




Is Argenica growing?

Current yearPrevious yearGrowGrow %
How rich?$5.5m$2m$2.2m52.0%

How much money is Argenica making?

Current yearPrevious yearGrowGrow %
Making money-$1m-$349.6k-$670.8k?
Net Profit Margin-82,922.6%-280,695.2%--

How much money comes from the company's main activities?

3. Financial Health of Argenica (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#916 / 1215

Most Revenue
#772 / 1215

Most Profit
#387 / 1215

Most Efficient
#1196 / 1215


Fundamentals of Argenica

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Argenica Therapeutics Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Argenica earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Argenica to the Biotechnology industry mean.
  • A Net Profit Margin of -200,456.4% means that $-2,004.56 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Argenica Therapeutics Ltd:

  • The MRQ is -200,456.4%. The company is making a huge loss. -2
  • The TTM is -82,922.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-200,456.4%TTM-82,922.6%-117,533.8%
TTM-82,922.6%YOY-280,695.2%+197,772.7%
TTM-82,922.6%5Y-167,682.3%+84,759.7%
5Y-167,682.3%10Y-167,682.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-200,456.4%-194.7%-200,261.7%
TTM-82,922.6%-273.6%-82,649.0%
YOY-280,695.2%-315.2%-280,380.0%
5Y-167,682.3%-539.0%-167,143.3%
10Y-167,682.3%-664.9%-167,017.4%
1.1.2. Return on Assets

Shows how efficient Argenica is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Argenica to the Biotechnology industry mean.
  • -25.9% Return on Assets means that Argenica generated $-0.26 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Argenica Therapeutics Ltd:

  • The MRQ is -25.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -23.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.9%TTM-23.0%-2.9%
TTM-23.0%YOY-17.6%-5.4%
TTM-23.0%5Y-20.7%-2.3%
5Y-20.7%10Y-20.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.9%-12.4%-13.5%
TTM-23.0%-12.5%-10.5%
YOY-17.6%-10.9%-6.7%
5Y-20.7%-15.3%-5.4%
10Y-20.7%-17.6%-3.1%
1.1.3. Return on Equity

Shows how efficient Argenica is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Argenica to the Biotechnology industry mean.
  • -28.2% Return on Equity means Argenica generated $-0.28 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Argenica Therapeutics Ltd:

  • The MRQ is -28.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -23.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.2%TTM-23.9%-4.3%
TTM-23.9%YOY-18.5%-5.4%
TTM-23.9%5Y-21.6%-2.3%
5Y-21.6%10Y-21.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.2%-15.2%-13.0%
TTM-23.9%-15.5%-8.4%
YOY-18.5%-13.1%-5.4%
5Y-21.6%-20.4%-1.2%
10Y-21.6%-20.9%-0.7%

1.2. Operating Efficiency of Argenica Therapeutics Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Argenica is operating .

  • Measures how much profit Argenica makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Argenica to the Biotechnology industry mean.
  • An Operating Margin of -100,246.5% means the company generated $-1,002.46  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Argenica Therapeutics Ltd:

  • The MRQ is -100,246.5%. The company is operating very inefficient. -2
  • The TTM is -41,477.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-100,246.5%TTM-41,477.7%-58,768.8%
TTM-41,477.7%YOY-140,363.8%+98,886.1%
TTM-41,477.7%5Y-83,857.4%+42,379.8%
5Y-83,857.4%10Y-83,857.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-100,246.5%-318.9%-99,927.6%
TTM-41,477.7%-267.4%-41,210.3%
YOY-140,363.8%-333.8%-140,030.0%
5Y-83,857.4%-517.0%-83,340.4%
10Y-83,857.4%-624.7%-83,232.7%
1.2.2. Operating Ratio

Measures how efficient Argenica is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Argenica Therapeutics Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.013-3.013
TTM-3.644-3.644
YOY-4.537-4.537
5Y-6.411-6.411
10Y-8.312-8.312

1.3. Liquidity of Argenica Therapeutics Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Argenica is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 12.29 means the company has $12.29 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Argenica Therapeutics Ltd:

  • The MRQ is 12.287. The company is very able to pay all its short-term debts. +2
  • The TTM is 52.264. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ12.287TTM52.264-39.977
TTM52.264YOY18.676+33.588
TTM52.2645Y37.869+14.395
5Y37.86910Y37.8690.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.2874.559+7.728
TTM52.2644.993+47.271
YOY18.6766.149+12.527
5Y37.8696.306+31.563
10Y37.8696.588+31.281
1.3.2. Quick Ratio

Measures if Argenica is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Argenica to the Biotechnology industry mean.
  • A Quick Ratio of 12.21 means the company can pay off $12.21 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Argenica Therapeutics Ltd:

  • The MRQ is 12.211. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 26.502. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ12.211TTM26.502-14.291
TTM26.502YOY12.970+13.532
TTM26.5025Y20.703+5.799
5Y20.70310Y20.7030.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.2113.881+8.330
TTM26.5024.502+22.000
YOY12.9705.772+7.198
5Y20.7035.816+14.887
10Y20.7036.032+14.671

1.4. Solvency of Argenica Therapeutics Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Argenica assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Argenica to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.08 means that Argenica assets are financed with 8.1% credit (debt) and the remaining percentage (100% - 8.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Argenica Therapeutics Ltd:

  • The MRQ is 0.081. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.040. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.081TTM0.040+0.041
TTM0.040YOY0.050-0.010
TTM0.0405Y0.045-0.004
5Y0.04510Y0.0450.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0810.311-0.230
TTM0.0400.298-0.258
YOY0.0500.269-0.219
5Y0.0450.377-0.332
10Y0.0450.409-0.364
1.4.2. Debt to Equity Ratio

Measures if Argenica is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Argenica to the Biotechnology industry mean.
  • A Debt to Equity ratio of 8.9% means that company has $0.09 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Argenica Therapeutics Ltd:

  • The MRQ is 0.089. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.043. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.089TTM0.043+0.045
TTM0.043YOY0.053-0.009
TTM0.0435Y0.047-0.004
5Y0.04710Y0.0470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0890.363-0.274
TTM0.0430.362-0.319
YOY0.0530.277-0.224
5Y0.0470.424-0.377
10Y0.0470.463-0.416

2. Market Valuation of Argenica Therapeutics Ltd

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Argenica generates.

  • Above 15 is considered overpriced but always compare Argenica to the Biotechnology industry mean.
  • A PE ratio of -31.87 means the investor is paying $-31.87 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Argenica Therapeutics Ltd:

  • The EOD is -28.908. Company is losing money. -2
  • The MRQ is -31.873. Company is losing money. -2
  • The TTM is -50.059. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-28.908MRQ-31.873+2.965
MRQ-31.873TTM-50.059+18.186
TTM-50.059YOY-10.587-39.473
TTM-50.0595Y-33.142-16.917
5Y-33.14210Y-33.1420.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-28.908-6.504-22.404
MRQ-31.873-7.165-24.708
TTM-50.059-8.417-41.642
YOY-10.587-19.810+9.223
5Y-33.142-18.328-14.814
10Y-33.142-18.049-15.093
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Argenica.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Argenica Therapeutics Ltd:

  • The MRQ is -32.001. Very Bad. -2
  • The TTM is -70.497. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-32.001TTM-70.497+38.496
TTM-70.497YOY-31.760-38.737
TTM-70.4975Y-62.750-7.747
5Y-62.75010Y-62.7500.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-32.001-4.287-27.714
TTM-70.497-6.137-64.360
YOY-31.760-13.849-17.911
5Y-62.750-12.525-50.225
10Y-62.750-11.713-51.037

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Argenica is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.50 means the investor is paying $4.50 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Argenica Therapeutics Ltd:

  • The EOD is 4.081. Neutral. Compare to industry.
  • The MRQ is 4.499. Neutral. Compare to industry.
  • The TTM is 8.284. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD4.081MRQ4.499-0.419
MRQ4.499TTM8.284-3.785
TTM8.284YOY0.846+7.438
TTM8.2845Y5.096+3.188
5Y5.09610Y5.0960.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.0811.991+2.090
MRQ4.4992.024+2.475
TTM8.2842.335+5.949
YOY0.8463.965-3.119
5Y5.0963.738+1.358
10Y5.0964.004+1.092
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Argenica Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0340.004+720%0.026+31%0.014+152%0.014+152%
Book Value Growth--1.5571.084+44%3.306-53%1.825-15%1.825-15%
Book Value Per Share--0.0960.074+29%0.036+168%0.058+66%0.058+66%
Book Value Per Share Growth--1.5641.085+44%3.306-53%1.825-14%1.825-14%
Current Ratio--12.28752.264-76%18.676-34%37.869-68%37.869-68%
Debt To Asset Ratio--0.0810.040+101%0.050+63%0.045+83%0.045+83%
Debt To Equity Ratio--0.0890.043+105%0.053+68%0.047+88%0.047+88%
Dividend Per Share----0%-0%-0%-0%
Eps---0.013-0.012-13%-0.004-70%-0.008-37%-0.008-37%
Eps Growth--0.9960.765+30%1.0000%0.812+23%0.812+23%
Free Cash Flow Per Share---0.009-0.010+9%-0.004-60%-0.007-20%-0.007-20%
Free Cash Flow Per Share Growth--0.9960.711+40%-0.036+104%0.462+116%0.462+116%
Free Cash Flow To Equity Per Share--0.0210.005+308%0.024-15%0.013+55%0.013+55%
Free Cash Flow To Equity Per Share Growth--1.0041.415-29%3.867-74%2.232-55%2.232-55%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.592--------
Intrinsic Value_10Y_min--0.477--------
Intrinsic Value_1Y_max---0.024--------
Intrinsic Value_1Y_min---0.024--------
Intrinsic Value_3Y_max---0.010--------
Intrinsic Value_3Y_min---0.010--------
Intrinsic Value_5Y_max--0.082--------
Intrinsic Value_5Y_min--0.071--------
Net Profit Margin---2004.564-829.226-59%-2806.952+40%-1676.823-16%-1676.823-16%
Operating Margin---1002.465-414.777-59%-1403.638+40%-838.574-16%-838.574-16%
Operating Ratio----0%-0%-0%-0%
Pb Ratio4.081-10%4.4998.284-46%0.846+432%5.096-12%5.096-12%
Pe Ratio-28.908+9%-31.873-50.059+57%-10.587-67%-33.142+4%-33.142+4%
Peg Ratio---32.001-70.497+120%-31.760-1%-62.750+96%-62.750+96%
Price Per Share0.390-10%0.4300.568-24%0.067+545%0.353+22%0.353+22%
Price To Total Gains Ratio11.321-10%12.482-17.422+240%3.090+304%-10.585+185%-10.585+185%
Profit Growth--0.0000.633-100%-4.195+245971745%-0.977+57257437%-0.977+57257437%
Quick Ratio--12.21126.502-54%12.970-6%20.703-41%20.703-41%
Return On Assets---0.259-0.230-11%-0.176-32%-0.207-20%-0.207-20%
Return On Equity---0.282-0.239-15%-0.185-34%-0.216-23%-0.216-23%
Total Gains Per Share--0.0340.004+720%0.026+31%0.014+152%0.014+152%
Usd Book Value--5526973.7624295016.795+29%2059553.021+168%3336960.892+66%3336960.892+66%
Usd Book Value Change Per Share--0.0230.003+720%0.017+31%0.009+152%0.009+152%
Usd Book Value Per Share--0.0640.049+29%0.024+168%0.038+66%0.038+66%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.009-0.008-13%-0.003-70%-0.006-37%-0.006-37%
Usd Free Cash Flow---509929.830-559130.428+10%-203566.942-60%-406746.077-20%-406746.077-20%
Usd Free Cash Flow Per Share---0.006-0.006+9%-0.002-60%-0.005-20%-0.005-20%
Usd Free Cash Flow To Equity Per Share--0.0140.003+308%0.016-15%0.009+55%0.009+55%
Usd Price Per Share0.259-10%0.2860.378-24%0.044+545%0.235+22%0.235+22%
Usd Profit---1560354.702-1020591.157-35%-349697.869-78%-733065.462-53%-733065.462-53%
Usd Revenue--778.401415.813+87%65705.028-99%28396.905-97%28396.905-97%
Usd Total Gains Per Share--0.0230.003+720%0.017+31%0.009+152%0.009+152%
 EOD+2 -3MRQTTM+20 -16YOY+15 -215Y+15 -2110Y+15 -21

3.2. Fundamental Score

Let's check the fundamental score of Argenica Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-28.908
Price to Book Ratio (EOD)Between0-14.081
Net Profit Margin (MRQ)Greater than0-2,004.564
Operating Margin (MRQ)Greater than0-1,002.465
Quick Ratio (MRQ)Greater than112.211
Current Ratio (MRQ)Greater than112.287
Debt to Asset Ratio (MRQ)Less than10.081
Debt to Equity Ratio (MRQ)Less than10.089
Return on Equity (MRQ)Greater than0.15-0.282
Return on Assets (MRQ)Greater than0.05-0.259
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Argenica Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.365
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets9,043
Total Liabilities736
Total Stockholder Equity8,307
 As reported
Total Liabilities 736
Total Stockholder Equity+ 8,307
Total Assets = 9,043

Assets

Total Assets9,043
Total Current Assets9,042
Long-term Assets9,042
Total Current Assets
Cash And Cash Equivalents 8,914
Net Receivables 72
Total Current Assets  (as reported)9,042
Total Current Assets  (calculated)8,987
+/- 56
Long-term Assets
Intangible Assets 1
Long-term Assets  (as reported)1
Long-term Assets  (calculated)1
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities736
Long-term Liabilities0
Total Stockholder Equity8,307
Total Current Liabilities
Accounts payable 672
Other Current Liabilities 19
Total Current Liabilities  (as reported)736
Total Current Liabilities  (calculated)691
+/- 45
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock13,065
Retained Earnings -5,504
Other Stockholders Equity 746
Total Stockholder Equity (as reported)8,307
Total Stockholder Equity (calculated)8,307
+/-0
Other
Capital Stock13,065
Cash and Short Term Investments 8,914
Common Stock Shares Outstanding 86,922
Liabilities and Stockholders Equity 9,043
Net Invested Capital 8,307
Net Tangible Assets 8,306
Net Working Capital 8,306



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
> Total Assets 
0
1,279
0
7,272
0
5,393
0
9,043
9,04305,39307,27201,2790
   > Total Current Assets 
1,278
1,278
7,271
7,271
5,392
5,392
9,042
9,042
9,0429,0425,3925,3927,2717,2711,2781,278
       Cash And Cash Equivalents 
0
1,222
0
7,144
0
5,307
0
8,914
8,91405,30707,14401,2220
       Net Receivables 
50
50
78
78
85
85
72
72
7272858578785050
       Other Current Assets 
6
6
0
0
0
0
0
0
00000066
   > Long-term Assets 
0
0
0
1
0
0
0
1
10001000
       Intangible Assets 
0
1
0
1
0
1
0
1
10101010
> Total Liabilities 
0
58
0
426
0
58
0
736
73605804260580
   > Total Current Liabilities 
58
58
426
426
58
58
736
736
73673658584264265858
       Accounts payable 
58
58
374
374
43
43
672
672
67267243433743745858
       Other Current Liabilities 
0
0
14
14
0
0
19
19
191900141400
   > Long-term Liabilities 00000000
       Other Liabilities 
0
0
0
0
0
0
0
0
00000000
> Total Stockholder Equity
0
1,220
0
6,847
0
5,334
0
8,307
8,30705,33406,84701,2200
   Retained Earnings -5,504-5,504-3,158-3,158-1,413-1,413-318-318
   Accumulated Other Comprehensive Income 00000000
   Capital Surplus 00000000
   Treasury Stock00000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue3
Cost of Revenue--
Gross Profit-3
 
Operating Income (+$)
Gross Profit-
Operating Expense--
Operating Income-4,3520
 
Operating Expense (+$)
Research Development2,496
Selling General Administrative1,748
Selling And Marketing Expenses-
Operating Expense-4,244
 
Net Interest Income (+$)
Interest Income3
Interest Expense-1
Other Finance Cost-0
Net Interest Income2
 
Pretax Income (+$)
Operating Income-4,352
Net Interest Income2
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-4,091-4,611
EBIT - interestExpense = -4,093
-4,091
-4,090
Interest Expense1
Earnings Before Interest and Taxes (EBIT)-4,092-4,090
Earnings Before Interest and Taxes (EBITDA)-4,090
 
After tax Income (+$)
Income Before Tax-4,091
Tax Provision-0
Net Income From Continuing Ops-4,091-4,091
Net Income-4,091
Net Income Applicable To Common Shares-4,091
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net259-2
 

Technicals of Argenica

1. Trend Indicators

1.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Argenica Therapeutics Ltd Daily Moving Averages ChartArgenica Therapeutics Ltd Daily Moving Averages Chart
1.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Let's take a look of the Moving Average Convergence/Divergence (MACD) of Argenica Therapeutics Ltd:

    Argenica Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) ChartArgenica Therapeutics Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
    1.3 Directional Movement Index (DMI)

    The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index).

    The ADX helps you determine the strength of a trend. Let's take a look of the ADX of Argenica Therapeutics Ltd:

    • The ADX is .
    Argenica Therapeutics Ltd Daily Directional Movement Index (DMI) ChartArgenica Therapeutics Ltd Daily Directional Movement Index (DMI) Chart
    1.4 Parabolic SAR

    Shows the current trend and potential entry and exit signals.

    • Parabolic SAR (stop and reverse) is a lagging trend indicator.
    • Shows the current trend.
    • Shows potential entry signals.
    • Shows  potential exit signals.
    • Can be used to place trailing stoplosses..
  • The Parabolic SAR is lower than the price. The current trend is up. +2
  • Argenica Therapeutics Ltd Daily Parabolic SAR ChartArgenica Therapeutics Ltd Daily Parabolic SAR Chart

    2. Momentum Indicators

    2.1 Relative Strength Index (RSI)

    Measures the speed and change of price movements.

    • Leading momentum indicator, meaning the signals are instant.
    • Ranges between 0 and 100.
    • Above 70 is considered overbought.
    • Below 30 is considered oversold.
    • Above or below 50 can also be used to determine price trend or support and resistance.
    • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
    • Can be used in many different ways
    • The RSI is below 50. -1
    • The RSI is below 30 and oversold. +2
    Argenica Therapeutics Ltd Daily Relative Strength Index (RSI) ChartArgenica Therapeutics Ltd Daily Relative Strength Index (RSI) Chart
    2.2 Stochastic Oscillator

    Compares a certain price to multiple prices ranging over time.

    • Leading momentum indicator, meaning the signals are instant.
    • Used to determine overbought and oversold areas much like the RSI.
    • Ranges between 0 and 100.
    • Above 80 is considered overbought.
    • Below 20 is considered oversold.
    • Consists of two lines named K and D.
    • K compares the highest high and lowest low on the selected price range.
    • The D line is a moving average of the K line.
    • Can be used to spot divergences
    • The Stochastic is below 50. -1
    • The Stochastic is below 30 and oversold. +2
    Argenica Therapeutics Ltd Daily Stochastic Oscillator ChartArgenica Therapeutics Ltd Daily Stochastic Oscillator Chart
    2.3 Commodity Channel Index (CCI)
    Argenica Therapeutics Ltd Daily Commodity Channel Index (CCI) ChartArgenica Therapeutics Ltd Daily Commodity Channel Index (CCI) Chart
    2.4 Chande Momentum Oscillator (CMO)
    Argenica Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) ChartArgenica Therapeutics Ltd Daily Chande Momentum Oscillator (CMO) Chart
    2.5 Williams %R
    Argenica Therapeutics Ltd Daily Williams %R ChartArgenica Therapeutics Ltd Daily Williams %R Chart

    3. Volatility Indicators

    3.1 Bollinger Bands
    Argenica Therapeutics Ltd Daily Bollinger Bands ChartArgenica Therapeutics Ltd Daily Bollinger Bands Chart
    3.2 Average True Range (ATR)
    Argenica Therapeutics Ltd Daily Average True Range (ATR) ChartArgenica Therapeutics Ltd Daily Average True Range (ATR) Chart

    4. Volume Indicators

    4.1 On-Balance Volume (OBV)
    Argenica Therapeutics Ltd Daily On-Balance Volume (OBV) ChartArgenica Therapeutics Ltd Daily On-Balance Volume (OBV) Chart
    4.2 Money Flow Index (MFI)
    Argenica Therapeutics Ltd Daily Money Flow Index (MFI) ChartArgenica Therapeutics Ltd Daily Money Flow Index (MFI) Chart

    5. Summary

    5.1. Notifications

    TypeNotificationDate
    PenkeCurrently no notifications for Argenica Therapeutics Ltd.

    5.2. Trading Signals

    DateIndicatorEntry signalExit signal
    2023-05-26MACD LONG ENTRY SHORT CLOSE
    STOCH SHORT ENTRY LONG CLOSE80 crossover to downside
    2023-05-29DMI SHORT ENTRY LONG CLOSE
    SAR SHORT ENTRY LONG CLOSEprice crossed sar to downside
    WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
    2023-06-01DMI LONG ENTRY SHORT CLOSE
    SAR LONG ENTRY SHORT CLOSEprice crossed sar to upside
    CCI LONG ENTRY SHORT CLOSE100 crossover to upside
    ATR LONG ENTRY SHORT CLOSE

    5.2. Technical Score

    Let's check the technical score of Argenica Therapeutics Ltd based on Penke's default Symbol scanner.

    Penke's Symbol Scanner

      
      
    IndicatorConditionValue
    OpenGreater thanClose0.365
    Total0/1 (0.0%)

    Comments

    Join the conversation.

    Leave a comment

    Stay informed about Argenica Therapeutics Ltd.

    Receive notifications about Argenica Therapeutics Ltd in your mailbox!